Cardiovascular disease prevention

Expert testimony on salt and cardiovascular disease － ER 4: The relationship between commercial interests and risk of cardiovascular disease － ER 5: Regional development of a population-based collaborative CVD prevention strategy: the experience of NHS West Midlands － ER 6: NICE guidance on the prevention of CVD at population level: evidence from the Co-operative Group － ER 7: Population and community programmes addressing multiple risk factors to prevent cardiovascular disease (CVD): addendum to qualitative study produced by Peninsula Technology Assessment Group for NICE: CVD programme – Heart of Mersey (HoM) － ER 8: Expert testimony paper on the independent evaluation of 'have a heart Paisley' phase one (Scotland's national CHD prevention demonstration project) － ER 9: Expert testimony on the public health harm caused by industrially produced trans fatty acids and actions to reduce and eliminate them from the food system in the UK － ER 10: Prevention of cardiovascular disease at a population level: evidence on interventions to address dietary fats － ER 11: CVD risk factors: paradigms and pathways － ER 12: CVD prevention in populations: lessons from other countries － ER 13: Will CVD prevention widen health inequalities? • NICE's guideline on overweight and obesity management:
